The Safety Switch in the Event of Toxicity

The development of n k sal immunitherapy is still relatively young, but a lot of people cite a paper that you co outhored in the new england journal of medicine back in two thousand 20 as early proof of concept for field. We reported and included patiencs with a non hotchkin limforma and patients with chronic limpocitic lucemia. And all of these were complete responses. We didn't see any evidence of toxicity. There was no sight o canvelesin drum, no neuro toxicity. Despite the fact that our encases were either partially match or fully missmatch with the recipient, wedidn't see any graft versus host disease in our patients